BioMarin, Amicus Agree To $4.8bn Buyout, Combining Rare Disease Portfolios

 
• By Joseph Haas
  
M&A
Hanmi’s Acquisition Follows Postive Early Clinical Data Of Aptose’s Lead Asset (Shutterstock)

More from Deals

More from Business